DxS Ltd
- PMID: 18384259
- DOI: 10.2217/14622416.9.4.463
DxS Ltd
Abstract
DxS is a personalized medicine company that meets the needs of the pharmaceutical industry for biomarkers and companion diagnostics to support the development and sales of cancer and other therapies. The company provides both biomarker products, which are used predominately during clinical trials, and companion diagnostics, which aid doctors in selecting therapies for patients. Working in partnership with drug companies, DxS offer validated biomarker assays to support drug development and then regulatory approval, by identifying likely responders to drug therapies. DxS have launched the world's first cancer mutation companion diagnostic to support Amgen's Vectibix colorectal cancer therapy. DxS kits detect mutations in oncogenes associated with cancer drug response. TheraScreen is the range of CE-marked diagnostic products for detecting mutations in the EGFR and K-RAS genes. Validated biomarker kits are available for research use for EGFR, RAS, RAF, BCR-ABL and other genes that show a correlation between patient mutation status and drug response.
Similar articles
-
DxS Ltd.Pharmacogenomics. 2003 Jan;4(1):97-101. doi: 10.1517/phgs.4.1.97.22580. Pharmacogenomics. 2003. PMID: 12517290
-
Promises of biomarkers in drug development--a reality check.Chem Biol Drug Des. 2007 Jun;69(6):381-94. doi: 10.1111/j.1747-0285.2007.00522.x. Chem Biol Drug Des. 2007. PMID: 17581232 Review.
-
[Development of biomarkers for molecular target drugs].Nihon Rinsho. 2015 Aug;73(8):1308-12. Nihon Rinsho. 2015. PMID: 26281683 Review. Japanese.
-
Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.Anticancer Res. 2010 Nov;30(11):4673-7. Anticancer Res. 2010. PMID: 21115922 Review.
-
GeneNews Limited: bringing the blood transcriptome to personalized medicine.Pharmacogenomics. 2012 Mar;13(4):381-5. doi: 10.2217/pgs.12.12. Pharmacogenomics. 2012. PMID: 22379995
Cited by
-
PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis.PLoS One. 2014 Sep 26;9(9):e107926. doi: 10.1371/journal.pone.0107926. eCollection 2014. PLoS One. 2014. PMID: 25260023 Free PMC article. Review.
-
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.Virchows Arch. 2008 Nov;453(5):417-31. doi: 10.1007/s00428-008-0665-y. Epub 2008 Sep 18. Virchows Arch. 2008. PMID: 18802721 Review.
-
Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.J Clin Pathol. 2012 Oct;65(10):940-4. doi: 10.1136/jclinpath-2012-200773. Epub 2012 Aug 7. J Clin Pathol. 2012. PMID: 22872705 Free PMC article.
-
454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples.Onco Targets Ther. 2013 Aug 5;6:1057-64. doi: 10.2147/OTT.S42369. eCollection 2013. Onco Targets Ther. 2013. PMID: 23950653 Free PMC article.
-
Next generation of antibody therapy for cancer.Chin J Cancer. 2011 May;30(5):293-302. doi: 10.5732/cjc.011.10123. Chin J Cancer. 2011. PMID: 21527062 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous